PARADYS: Patient-specific Ranking of Genes Driving Dysregulation in Cancer and Therapeutic Implications
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
In cancer, most somatic mutation are so-called passenger mutations with no functional impact on disease development. Only a subset of the mutations act as drivers and are responsible for tumor growth and progression. Identifying patient-specific driver mutations is one of the main challenges in precision oncology. Existing computational methods to identify patient-specific cancer drivers either integrate mutation and expression data with a single aggregated gene interaction network or use personalized gene interaction networks without considering mutation data. As yet, no methods making use of both patient-specific mutation and gene network data exist. For this reason, we developed PARADYS (PAtient-specific RAnking of genes driving DYSregulation in cancer), a computational tool for personalized detection and impact scoring of genes driving dysregulation in cancer (https://github.com/bionetslab/PARADYS). On several cancer cohorts, we show that PARADYS is able to make robust predictions by integrating patient-specific mutation and dysregulation data. Furthermore, PARADYS’ driver predictions allow for patient stratification into functionally coherent and biologically distinct subgroups. In particular, a case study in prostate cancer reveals a subgroup of patients with infiltration of dendritic cells in the tumor micro-environment and unexpectedly high survival times, highlighting the potential of dendritic cell therapy in prostate cancer.